Seva has been selected by the U.S. Food and Drug Administration (FDA) to participate in the Total Product Life Cycle Advisory Program (TAP) Pilot, becoming one of the first organizations to join the program’s expansion into ophthalmic devices in 2025.

TAP’s primary goal is to expedite the development of high-quality, safe, effective, and innovative medical devices. We’ll contribute our over 40 years of eye care expertise to support the FDA in guiding strategic decision-making during device development, ensuring high-quality outcomes for patients and healthcare providers.

“Investing in new technologies to further eye care access is one of the Seva Foundation’s key drivers for success. Our involvement in the TAP Pilot is a meaningful step for Seva, as together with manufacturers, we can advance solutions that help end avoidable blindness and provide everyone the chance to see the world clearly.”

– Kate Moynihan, CEO/Executive Director